Enhancing glioblastoma treatment using cisplatin-gold-nanoparticle conjugates and targeted delivery with magnetic resonance-guided focused ultrasound
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Glioblastoma (GBM) is the most common and aggressive primary brain tumor resulting in high rates of morbidity and mortality. A strategy to increase the efficacy of available drugs and enhance the delivery of chemotherapeutics through the blood brain barrier (BBB) is desperately needed. We investigated the potential of Cisplatin conjugated gold nanoparticle (GNP-UP-Cis) in combination with MR-guided Focused Ultrasound (MRgFUS) to intensify GBM treatment. Viability assays demonstrated that GNP-UP-Cis greatly inhibits the growth of GBM cells compared to free cisplatin and shows marked synergy with radiation therapy. Additionally, increased DNA damage through γH2AX phosphorylation was observed in GNP-UP-Cis treated cells, along with enhanced platinum concentrations. In vivo, GNP-UP-Cis greatly reduced the growth of GBM tumors and MRgFUS led to increased BBB permeability and GNP-drug delivery in brain tissue. Our studies suggest that GNP-Cis conjugates and MRgFUS can be used to focally enhance the delivery of targeted chemotherapeutics to brain tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cellular processing of platinum anticancer drugs
Wang, D., & Lippard, S. J. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1691 · Cited by 3,801
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335
Clinical trial of blood-brain barrier disruption by pulsed ultrasound
Carpentier, A., Canney, M., Vignot, A., Reina, V., Beccaria, K., Horodyckid, C., Karachi, C., Leclercq, D., Lafon, C., Chapelon, J.-Y., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6086 · Cited by 757 · cited 2×
“In an ongoing phase I/IIa study on patients suffering from relapsing GBM,MRgFUS is being used to increase the delivery of carboplatin.(46) Preliminary results indicate that in patients with confirmed extended BBB opening, the region encompassed by the ultrasonic beam did not show tumor progression on follow-up MRIs at…”
BackgroundMethodYang, C., Uertz, J., Yohan, D., & Chithrani, B. D. (2014) · Nanoscale · doi:10.1039/c4nr02535k · Cited by 156
Cited by
The blood–brain barrier: Structure, regulation and drug delivery
Wu, D., Chen, Q., Chen, X., Han, F., Chen, Z., & Wang, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01481-w · Cited by 1,906
Magnetic nanoparticles in nanomedicine: a review of recent advances
Wu, K., Su, D., Liu, J., Saha, R., & Wang, J.-P. (2019) · Nanotechnology · doi:10.1088/1361-6528/ab4241 · Cited by 509
Applications of focused ultrasound in the brain: from thermoablation to drug delivery
Meng, Y., Hynynen, K., & Lipsman, N. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-020-00418-z · Cited by 505
Self-citationMakovec, T. (2019) · Radiology and Oncology · doi:10.2478/raon-2019-0018 · Cited by 480
Hersh, A. M., Alomari, S., & Tyler, B. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084153 · Cited by 478
Metadata
- Authors
- Coluccia, D., Figueiredo, C. A., Wu, M. Y., Riemenschneider, A. N., Diaz, R., Luck, A., Smith, C., Das, S., Ackerley, C., O’Reilly, M., Hynynen, K., & Rutka, J. T.
- Venue
- Nanomedicine: Nanotechnology, Biology and Medicine
- Publisher
- Elsevier BV
- Published
- 2018-06
- Volume
- 14
- Issue
- 4
- Pages
- 1137-1148
- ISSN
- 1549-9634 (ISSN-L)
- OpenAlex
- W2789998517
- Cited by
- 139
- References
- 4
- FWCI
- 5.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Enhancing glioblastoma treatment using cisplatin-gold-nanoparticle conjugates and targeted delivery with magnetic resonance-guided focused ultrasound. https://app.cochat.ai/papers/10.1016/j.nano.2018.01.021
- The paper
- Coluccia, D., Figueiredo, C. A., Wu, M. Y., Riemenschneider, A. N., Diaz, R., Luck, A., Smith, C., Das, S., Ackerley, C., O’Reilly, M., Hynynen, K., & Rutka, J. T. (2018). Enhancing glioblastoma treatment using cisplatin-gold-nanoparticle conjugates and targeted delivery with magnetic resonance-guided focused ultrasound. Nanomedicine: Nanotechnology, Biology and Medicine. https://doi.org/10.1016/j.nano.2018.01.021
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.